Background: Several studies have reported that insulin resistance and compensatory hyperinsulinemia increased lipid peroxidation, suggesting the linking to each other. We investigated the relationships between insulin resistance index HOMA-IR and lipid peroxidation, plasma antioxidant status in non-diabetic, hypercholesterolemic patients. Methods: We measured the urinary excretion of 8-epi-prostaglandin F2α(PGF2α) levels as a measure of lipid peroxidation in vivo, total radical trapping antioxidant potential (TRAP) and fat-soluble antioxidant vitamins in 76 non-diabetic subjects with hypercholesterolemia (mean age 59 years, 25 males and 51 females). Insulin resistance was evaluated by homeostasis model assessment (HOMA-IR) derived from fasting glucose and insulin concentrations. Results: HOMA-IR was positively correlated with the urinary excretion of PGF2α (r = 0.222, p < 0.05) and negatively correlated with the TRAP (r = –0.211, p < 0.05) in total subjects. Furthermore, there were significant inverse relationships between HOMA-IR and lipid corrected fat-soluble vitamins such as β-carotene (r = –0.297, p < 0.01) and γ-tocopherol (r = –0.243, p < 0.05) and also significant inverse relation was found between lipid corrected β-carotene and the urinary PGF2αexcretion (r = –0.205, p < 0.05). When total subjects were divided into three groups according to tertiles of HOMA-IR, significant differences in urinary PGF2αexcretion (p < 0.05) and lipid corrected β-carotene (p < 0.005) among the three groups were observed. The highest HOMA-IR group had the higher levels of urinary PGF2αexcretion and lower levels of plasma β-carotene compared with the lowest HOMA-IR group. Conclusion: Our data showed that the insulin resistance of hypercholesterolemic patients increased oxidative stress and negatively influenced plasma antioxidant system. These results provide evidence in understanding mechanism linking insulin resistance and oxidative stress accompanied by reduced antioxidant system.

Keywords:
Insulin resistance, Lipid peroxidation, Antioxidant, Hypercholesterolemia
This content is only available via PDF.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.